Accessibility Menu
Tyra Biosciences logo

Tyra Biosciences(NASDAQ) TYRA

Current Price$31.89
Market Cap$1.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+19%
5 YearN/A
1 Year+199%
1 Month+10%
Tyra Biosciences last closing stock price
MetricPriceDate
Last closeUSD 31.062026-07-20
Tyra Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.94%USD 32.672026-07-13
1 month+9.66%USD 28.322026-06-18
3 month-15.36%USD 36.692026-04-21
Year to date+18.12%USD 26.292025-12-31
1 year+198.89%USD 10.392025-07-18
3 year+93.13%USD 16.082023-07-21
Since inception+19.44%USD 26.002021-09-15

Tyra Biosciences Financials at a Glance

Market Cap

$1.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$131.11M

EPS (TTM)

-$2.17

P/E Ratio

-14.28

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$31.89

Volume

8,905

Open

$31.54

Previous Close

$31.89

Daily Range

$31.08 - $31.89

52-Week Range

$9.96 - $40.65

Estimated Earnings Date

Aug 13, 2026

TYRA News

f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Jonathan PoncianoMay 17, 2026
BuyAlert-Red.png

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Jonathan PoncianoMar 20, 2026
SellAlert-Red.png

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally

Sarah SidlowDec 23, 2025
Foolcom-Featured.png

Tyra Biosciences Narrows Loss in Q2

Motley Fool Markets TeamAug 14, 2025

TYRA: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tyra Biosciences

Tyra makes new medicines for people with cancer or rare bone conditions. These treatments help patients whose bodies do not respond well to current drugs. The company uses a special computer platform to design precise pills.

What Tyra Is Building

  • FGFR3 Program: Oral drug for bladder cancers and achondroplasia, which is a condition affecting bone growth; currently in multiple Phase 2 trials.
  • TYRA-430: Targeted therapy for liver cancer caused by specific gene signaling; currently in a Phase 1 global trial.
  • TYRA-200: Medicine designed to work against cancer mutations that resist other drugs; focused on a rare bile duct cancer.
  • SNÅP Platform: Internal technology using molecular snapshots to help scientists predict which drug designs will work best.

How Did the Company Expand?

  • Raised $147.9 million in net proceeds during Q1 2026 through an at-the-market stock offering.
  • Entered a sales agreement with TD Securities in May 2025 to support ongoing capital needs.
  • Secured $200 million in February 2024 from a private sale of stock and warrants to institutional investors.
  • Started the dabogratinib 3x3 strategy to test its lead drug in three major medical indications simultaneously.

The Tech Behind the Trials

Tyra uses its proprietary SNÅP platform to create drugs that are more selective than older treatments. This precision helps target specific proteins while reducing side effects on healthy tissue.

A Factual Look at Finances

  • Net loss reached $39.3 million in Q1 2026, a 39.6% deepening from the same period in 2025.
  • Research and development spending increased to $33.5 million in Q1 2026, up from $25 million in Q1 2025.
  • Cash and marketable securities totaled $383.5 million on March 31, 2026, following recent equity sales.
  • Operating cash flow reached negative $32.6 million in Q1 2026, a 27.9% deepening from the previous year.

Bottom Line

Tyra is moving from early research to mid-stage clinical testing of its lead drug candidates. The company maintains a significant cash reserve to support its development pipeline into 2028.

AI Generated • May 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

87

CEO

Todd J. Harris, PhD

Website

www.tyra.bio

Headquarters

Carlsbad, CA 92008, US

TYRA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-42.66%

Return on Capital

-50.10%

Return on Assets

-31.82%

Earnings Yield

-7.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.47M

Volume

8.90K

Avg. Volume

882.28K

Financials (TTM)

Gross Profit

-$138.00K

Operating Income

-$142.91M

EBITDA

-$130.56M

Operating Cash Flow

-$102.26M

Capital Expenditure

-$215.00K

Free Cash Flow

-$102.47M

Cash & ST Invst.

$383.47M

Total Debt

$5.70M

Tyra Biosciences Performance Analysis

Tyra Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tyra Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Tyra Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.32108.2%
20232023-12-31USD -1.6222.6%
20242024-12-31USD -1.51-6.6%
20252025-12-31USD -2.0133.1%
Tyra Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-6.4%
Q42025-12-31-14.0%
Q12026-03-31-12.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$138.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$21.23M

N/A

Employees

87

N/A

Net Income

-$39.31M

-39.6%

EBITDA

-$39.17M

-39.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$383.47M

+20.2%

Total Debt

$5.70M

-6.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$5.21M

-8.5%

Short Term Debt

$488.00K

+14.6%

Return on Assets

-31.82%

N/A

Return on Invested Capital

-36.38%

N/A

Free Cash Flow

-$32.66M

-28.2%

Operating Cash Flow

-$32.57M

-27.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRVIMaravai LifeSciences Holdings, Inc.
$7.10+1.57%
NBTXNanobiotix S.A.
$39.42+10.33%
DAWNDay One Biopharmaceuticals, Inc.
$21.53+0.00%
SVRASavara Inc.
$5.84+6.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.26+0.01%
NOKNokia
$10.63+0.05%
MARAMara Holdings
$12.25+0.05%
AALAmerican Airlines Group
$15.28+0.01%

Questions About TYRA

What is the current price of Tyra Biosciences?

Tyra Biosciences is trading at $31.89 per share.

What is the 52-week range for Tyra Biosciences?

Over the past 52 weeks, Tyra Biosciences has traded between $9.96 and $40.65.

How much debt does Tyra Biosciences have?

As of the most recent reporting period, Tyra Biosciences reported total debt of $5.70M.

How much cash does Tyra Biosciences have on hand?

Tyra Biosciences reported $84.96M in cash and cash equivalents in its most recent financial results.

What is Tyra Biosciences’s dividend yield?

Tyra Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services